WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU), which is pioneering the use of genetic information for the prevention and improved management of certain chronic conditions of aging, today announced that it has entered into a three year Preferred Participation Agreement with Renaissance Health Service Corporation, and certain of its affiliates and subsidiaries, (collectively “RHSC”). Pursuant to the Agreement, RHSC has agreed to reimburse Interleukin a fixed price for each PST® genetic test that it processes for a customer of RHSC. Interleukin’s proprietary PST® genetic risk panel for periodontal disease severity and tooth loss susceptibility addresses the need to identify individuals who are at greater risk of severe periodontitis, a primary cause of tooth loss.
